Phase 2 Study of TXA127 in Post-ischemic Stroke Patients
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a 50-patient, Phase 2, double-blind, randomized, placebo-controlled, hybrid
decentralized study to evaluate the safety and efficacy of daily subcutaneous (SC) injection
of TXA127 in post-ischemic stroke patients. Subjects will receive either TXA127 0.5mg/kg or
placebo for 12 weeks started 6 to 24 months post ischemic stroke, and they will have a 12
week follow up visit after treatment has ended. The primary efficacy outcome measure is
individual patient absolute change from baseline in motor and sensory functions as measured
by the Fugl-Meyer Assessment of Upper Extremity (FMA-UE) 12 weeks after start of treatment.